Over-the-Counter Potassium Supplements: Dosing in mEq
Over-the-counter potassium supplements in the United States are limited by FDA regulation to 99 mg (approximately 2.5 mEq) per tablet or capsule, which is substantially lower than prescription formulations that typically provide 8-20 mEq per dose.
Understanding the Conversion
The conversion between milligrams and milliequivalents for potassium is straightforward:
- 39 mg of elemental potassium = 1 mEq
- 99 mg (OTC maximum) = approximately 2.5 mEq
This means achieving therapeutic potassium supplementation with OTC products requires multiple tablets throughout the day.
Clinical Context for Potassium Supplementation
Prescription vs. OTC Dosing
Prescription potassium formulations provide significantly higher doses per unit:
- Slow-K: 8 mEq per tablet 1
- K-Tab: 10 mEq per tablet 1
- Sustained-release formulations: 20 mEq per tablet 2
In clinical practice, patients with heart failure or those on diuretics typically require 20-60 mEq daily to maintain serum potassium in the 4.5-5.0 mEq/L range 3. This would necessitate taking 8-24 OTC tablets daily, which is impractical and raises adherence concerns.
Bioavailability Considerations
Research demonstrates that potassium from various sources is highly bioavailable (>94%) 4. However, the absorption pattern differs:
- Immediate-release (elixir): Peak urinary excretion at 2.2 hours
- Sustained-release tablets: Peak at 5.5 hours 2
Complete absorption occurs within 24 hours regardless of formulation 5.
Important Safety Considerations
When OTC Potassium Is Inappropriate
OTC potassium supplements should be avoided entirely in patients taking:
- ACE inhibitors (lisinopril, enalapril, etc.)
- Angiotensin receptor blockers (losartan, valsartan, etc.)
- Aldosterone antagonists (spironolactone, eplerenone)
- Potassium-sparing diuretics (amiloride, triamterene)
These medications reduce potassium excretion, and adding supplementation creates life-threatening hyperkalemia risk 3, 6, 7.
Hyperkalemia Risk Thresholds
Guidelines define dangerous potassium levels as:
- >5.0 mEq/L: Use ACE inhibitors and aldosterone antagonists with caution 7
- >6.0 mEq/L: Discontinue RAASi therapy 8
- >6.5 mEq/L: Severe hyperkalemia requiring urgent treatment 9
Patients with chronic kidney disease (CKD) are at particularly high risk, as renal potassium excretion is maintained only until GFR decreases below 10-15 mL/min/1.73 m² 10.
Alternative Approaches to Potassium Supplementation
Dietary Sources
Dietary potassium is equally bioavailable to supplements and may be preferable 4. However, achieving therapeutic doses through diet alone is challenging:
- Potatoes provide substantial potassium but require large portions
- Salt substitutes (25-30% potassium chloride) can provide 10-20 mEq per day 6
Medical Foods and Supplements
Recent analysis of OTC products shows variable citrate content 11:
- Moonstone powder: 63.9 mEq citrate per serving (highest)
- LithoBalance: 33.5 mEq per serving
- NOW potassium citrate: Most cost-effective at $0.04 per 10 mEq
However, these products are marketed for kidney stone prevention, not general potassium supplementation, and their role in managing hypokalemia is not established.
Clinical Algorithm for Potassium Supplementation
For patients requiring potassium supplementation:
- Check medication list first: If on RAASi therapy, do not add OTC potassium without nephrology consultation
- Assess renal function: If GFR <30 mL/min/1.73 m², avoid OTC potassium
- Verify baseline potassium: If >4.5 mEq/L, supplementation is unnecessary
- For mild hypokalemia (3.5-4.0 mEq/L): Dietary modification is first-line
- For moderate hypokalemia (<3.5 mEq/L): Prescription potassium is required; OTC doses are insufficient
Common Pitfalls
- Underestimating required dose: OTC potassium at 2.5 mEq per tablet cannot achieve therapeutic supplementation for most clinical indications
- Ignoring drug interactions: The most dangerous error is adding potassium to patients on RAASi therapy without monitoring
- Assuming "natural" is safer: Salt substitutes contain the same potassium chloride as prescription products and carry identical hyperkalemia risks 10
- Inadequate monitoring: Serum potassium should be rechecked within 2-3 days of initiating supplementation, then at 7 days 7
The practical reality is that OTC potassium supplements at 99 mg (2.5 mEq) are inadequate for most clinical scenarios requiring potassium supplementation, and prescription formulations providing 8-20 mEq per dose are necessary for effective treatment.